Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 11/20 | 1.00 |
| ▸ | FUCA1 | P04066 | 4/20 | 0.44 |
| ▸ | GLA | P06280 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | GLB1 | P16278 | 2/20 | 0.44 |
| ▸ | PYGL | P06737 | 1/20 | 0.39 |
| ▸ | GBA2 | Q9HCG7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6857546 | 1.00 | GBA1 (1.00) | GBA1FUCA1GLAGAAGLB1 | |
| Hydrochloric Acid SCHEMBL20561370 | 0.98 | GBA1 (0.96) | GBA1FUCA1GLAGAAGLB1 | |
| Hydrochloric Acid SCHEMBL1627205 | 0.98 | GBA1 (0.96) | GBA1FUCA1GLAGAAGLB1 | |
| Hydrochloric Acid SCHEMBL20582653 | 0.98 | GBA1 (0.96) | GBA1FUCA1GLAGAAGLB1 | |
| Hydrochloric Acid SCHEMBL27867105 | 0.98 | GBA1 (0.96) | GBA1FUCA1GLAGAAGLB1 | |
| Hydrochloric Acid SCHEMBL1651911 | 0.98 | GBA1 (0.96) | GBA1FUCA1GLAGAAGLB1 | |
| Hydrochloric Acid SCHEMBL27867104 | 0.98 | GBA1 (0.96) | GBA1FUCA1GLAGAAGLB1 | |
| SCHEMBL20561339 | 0.78 | GBA1 (1.00) | GBA1FUCA1GLAGAAGLB1 | |
| SCHEMBL20561338 | 0.78 | GBA1 (1.00) | GBA1FUCA1GLAGAAGLB1 | |
| SCHEMBL17578923 | 0.78 | GBA1 (1.00) | GBA1FUCA1GLAGAAGLB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3143875-B1 | NOVEL COMPOSITIONS FOR PREVENTING AND/OR TREATING DEGENERATIVE DISORDERS OF THE CENTRAL NERVOUS SYSTEM | AMICUS THERAPEUTICS INC (US) | 2020-05-27 | — | — | EP | disclosed |
| EP-3143875-B1 | NOVEL COMPOSITIONS FOR PREVENTING AND/OR TREATING DEGENERATIVE DISORDERS OF THE CENTRAL NERVOUS SYSTEM | AMICUS THERAPEUTICS INC (US) | 2020-05-27 | — | — | EP | disclosed |
| US-10035766-B2 | Compositions for preventing and/or treating lysosomal storage disorders | AMICUS THERAPEUTICS, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| US-10035766-B2 | Compositions for preventing and/or treating lysosomal storage disorders | AMICUS THERAPEUTICS, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| US-9931353-B2 | Method for treating cerebral amyloid angiopathy using pharmacological chaperones to increase the activity of gangliosidases | AMICUS THERAPEUTICS, INC. (US) | 2018-04-03 | — | — | US | disclosed |
| US-9931353-B2 | Method for treating cerebral amyloid angiopathy using pharmacological chaperones to increase the activity of gangliosidases | AMICUS THERAPEUTICS, INC. (US) | 2018-04-03 | — | — | US | disclosed |
| EP-2957295-B1 | METHOD FOR TREATING ALZHEIMER'S DISEASE USING PHARMACOLOGICAL CHAPERONES TO INCREASE THE ACTIVITY OF GANGLIOSIDASES | AMICUS THERAPEUTICS INC (US) | 2017-08-02 | — | — | EP | disclosed |
| EP-3143875-A1 | NOVEL COMPOSITIONS FOR PREVENTING AND/OR TREATING DEGENERATIVE DISORDERS OF THE CENTRAL NERVOUS SYSTEM | Amicus Therapeutics, Inc. (US) | 2017-03-22 | — | — | EP | disclosed |
| EP-3143875-A1 | NOVEL COMPOSITIONS FOR PREVENTING AND/OR TREATING DEGENERATIVE DISORDERS OF THE CENTRAL NERVOUS SYSTEM | Amicus Therapeutics, Inc. (US) | 2017-03-22 | — | — | EP | disclosed |
| EP-2490532-B1 | NOVEL COMPOSITIONS FOR PREVENTING AND/OR TREATING DEGENERATIVE DISORDERS OF THE CENTRAL NERVOUS SYSTEM | AMICUS THERAPEUTICS INC (US) | 2016-11-23 | — | — | EP | disclosed |
| US-20140080871-A1 | Novel Compositions for Preventing and/or Treating Degenerative Disorders of the Central Nervous System | AMICUS THERAPEUTICS, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| US-20140080871-A1 | Novel Compositions for Preventing and/or Treating Degenerative Disorders of the Central Nervous System | AMICUS THERAPEUTICS, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| US-20120309788-A1 | Method for Treating Alzheimer's Disease Using Pharmacological Chaperones To Increase The Activity of Gangliosidases | AMICUS THERAPEUTICS, INC. (US) | 2012-12-06 | — | — | US | disclosed |
| US-20120309788-A1 | Method for Treating Alzheimer's Disease Using Pharmacological Chaperones To Increase The Activity of Gangliosidases | AMICUS THERAPEUTICS, INC. (US) | 2012-12-06 | — | — | US | disclosed |
| WO-2011049736-A1 | NOVEL COMPOSITIONS FOR PREVENTING AND/OR TREATING DEGENERATIVE DISORDERS OF THE CENTRAL NERVOUS SYSTEM | AMICUS THERAPEUTICS, INC. (US) | 2011-04-28 | — | — | WO | disclosed |
| WO-2011049787-A1 | METHOD FOR TREATING ALZHEIMER'S DISEASE USING PHARMACOLOGICAL CHAPERONES TO INCREASE THE ACTIVITY OF GANGLIOSIDASES | AMICUS THERAPEUTICS, INC. (US) | 2011-04-28 | — | — | WO | disclosed |
| US-20110092541-A1 | NOVEL COMPOSITIONS FOR PREVENTING AND/OR TREATING DEGENERATIVE DISORDERS OF THE CENTRAL NERVOUS SYSTEM | AMICUS THERAPEUTICS, INC. (US) | 2011-04-21 | — | — | US | disclosed |
| US-20110092541-A1 | NOVEL COMPOSITIONS FOR PREVENTING AND/OR TREATING DEGENERATIVE DISORDERS OF THE CENTRAL NERVOUS SYSTEM | AMICUS THERAPEUTICS, INC. (US) | 2011-04-21 | — | — | US | disclosed |
| US-20110091442-A1 | NOVEL COMPOSITIONS FOR PREVENTING AND/OR TREATING LYSOSOMAL STORAGE DISORDERS | AMICUS THERAPEUTICS, INC. (US) | 2011-04-21 | — | — | US | disclosed |
| US-20110091442-A1 | NOVEL COMPOSITIONS FOR PREVENTING AND/OR TREATING LYSOSOMAL STORAGE DISORDERS | AMICUS THERAPEUTICS, INC. (US) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309788-A1 | Method for Treating Alzheimer's Disease Using Pharmacological Chaperones To Increase The Activity of Gangliosidases | GBA1, GBA3, ASAH1 | GBA1 1/4885FUCA1 57/4885GLA 6/4885 |
| US-20140080871-A1 | Novel Compositions for Preventing and/or Treating Degenerative Disorders of the Central Nervous System | GAP43, CHAT, PMP22 | GBA1 337/4885FUCA1 626/4885GLA 1323/4885 |
| US-20110091442-A1 | NOVEL COMPOSITIONS FOR PREVENTING AND/OR TREATING LYSOSOMAL STORAGE DISORDERS | GAA, GBA1, MAN2B1 | GBA1 2/4885FUCA1 78/4885GLA 14/4885 |
| US-20110092541-A1 | NOVEL COMPOSITIONS FOR PREVENTING AND/OR TREATING DEGENERATIVE DISORDERS OF THE CENTRAL NERVOUS SYSTEM | GAP43, CHAT, PMP22 | GBA1 337/4885FUCA1 626/4885GLA 1323/4885 |
| US-10035766-B2 | Compositions for preventing and/or treating lysosomal storage disorders | GAA, GBA1, MAN2B1 | GBA1 2/4885FUCA1 78/4885GLA 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.